Previous 10 |
home / stock / pphof / pphof news
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin ® studies; first-patient-in expected in June 2023 Commitment structured as a mix of secured debt and subordinated debt mandator...
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin ® Phase 3 development costs, including those involving both COPILOT and COPA SGI has invested in Spexis as part of the ColiFin ...
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platform Data support moving forward to Phase 2 in cystic fibrosis and non-cystic fibrosis bronchiect...
SPEXIS AG press release ( OTC:PPHOF ): 1H net loss of CHF 10M. Total cash position was CHF 7.0M (cash and cash equivalents) as of June 30, 2022, which is expected to finance operations through January 2023. For further details see: SPEXIS AG reports 1H results
Polyphor publishes invitation to Extraordinary General Meeting and announces financial results for the first half 2021 - EGM on October 28, 2021 to be held to prepare merger with EnBiotix Inc, with shareholders not physically present, in accordance with COVID-19 ordinances. - Pre-EG...
Polyphor and EnBiotix have signed a merger agreement. EnBiotix acquires Inhaled Murepavadin at an agreed valuation of USD 10 million in exchange for 2'599'655 of common shares of EnBiotix (15.4% fully diluted of EnBiotix). Prior to closing EnBiotix expects to finalize a financing ...
News, Short Squeeze, Breakout and More Instantly...
Polyphor AG Registered Shares Company Name:
PPHOF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Fin...
ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. ...
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin ® program in cystic fi...